Autopsy report · NCT04264208

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

“Lack of accrual due to pandemic and logistics”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Andrei Iagaru

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

68-Ga RM2.; 68-Ga PSMA11; PET/MRI

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation
  “Lack of funding and other logistical issues” (67% match in meaning)
• Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
  “Low accrual due to COVID-19 pandemic.” (64% match in meaning)
• Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
  “insufficient recruitment due to the pandemic situation” (64% match in meaning)
• Vitamin E for NASH Treatment in HIV Infected Individuals
  “lack of coordinator resources and lack of access to study resources during and due to the COVID pandemic” (63% match in meaning)
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.